Future growth expectations in sales/revenue/volumes?

Windlas Biotech is optimistic about future growth, especially in trade generics and injectables. Oral solids capacity utilization was around 60-62% in FY '25, with potential revenue of INR 800+ crores from current capacity. With Plant 6, oral solids revenue capacity is expected to reach INR 1,000 crores. Injectables sales were INR 6 crores in FY '25 (mostly Q4); ramp-up expected but timelines not specifically disclosed. The company aims for steady increase in trade generics and export businesses, expecting exports to become a significant vertical over time. Margin expansion is anticipated as i

Future growth expectations in earnings/operating earnings/profits/EPS?

Windlas Biotech expects margin expansion in FY '26 and FY '27 as injectable business costs get absorbed and trade generics and export proportions grow. The company remains optimistic about sustaining strong revenue growth, backed by capacity expansions like Plant 6 aimed at increasing oral solids capacity to INR1,000+ crores. Operational efficiencies and diversification of client base are key focus areas supporting long-term value enhancement. Despite cost pressures like a 25% minimum wage increase, the company sustained operating margins and expects improved profitability as ramp-up in inject

Current/ Expected Orderbook/ Pending Orders?

The call transcript does not specify the current or expected order book or pending orders quantitatively. It mentions that the injectable facility has been approved by several large customers and some injectable products have been commercialized. Management highlights active efforts on trade generics and CDMO verticals with new customer additions and broader product portfolios. There are ongoing initiatives in export verticals, including filing dossiers and entering newer markets, indicating pipeline building. Plant 6 oral solids facility is being modernized and expected to be operational with

Windlas Biotech LtdQ1 FY26

Windlas Biotech Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹949P/E: 26.6Market Cap: ₹1.8K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Windlas Biotech is optimistic about future growth, especially in trade generics and injectables.
→Oral solids capacity utilization was around 60-62% in FY '25, with potential revenue of INR 800+ crores from current capacity.
→With Plant 6, oral solids revenue capacity is expected to reach INR 1,000 crores.
→Injectables sales were INR 6 crores in FY '25 (mostly Q4); ramp-up expected but timelines not specifically disclosed.
→The company aims for steady increase in trade generics and export businesses, expecting exports to become a significant vertical over time.
→Margin expansion is anticipated as injectable business ramps up and fixed costs stabilize.
→Growth in trade generics has been strong (~40% CAGR last 5 years), with aspirations to reach levels of large-cap peers.
→Management emphasizes execution capability, management systems, and geographic expansion as keys to sustaining growth.
→Capacity expansions and market penetration efforts are ongoing, with the injectable business seen as the future growth driver.

Margin guidance

Category 3

→Windlas Biotech expects margin expansion in FY '26 and FY '27 as injectable business costs get absorbed and trade generics and export proportions grow.
→The company remains optimistic about sustaining strong revenue growth, backed by capacity expansions like Plant 6 aimed at increasing oral solids capacity to INR1,000+ crores.
→Operational efficiencies and diversification of client base are key focus areas supporting long-term value enhancement.
→Despite cost pressures like a 25% minimum wage increase, the company sustained operating margins and expects improved profitability as ramp-up in injectables progresses.
→Dividend policy of paying 20% of profits is intended to continue, reflecting confidence in earnings growth.
→No specific forward guidance on exact numbers shared, citing competitive sensitivities, but internal targets and tracking mechanisms are in place for injectable business breakeven and subsequent profit growth.
→Sustained ROCE and ROE greater than 20% alongside ongoing capacity expansions signify robust financial health.

3 more insights locked — sign up free to unlock

Fundraise plans

- Windlas Biotech has around INR215 crores in cash with strong cash generation. - The company has debt-taking capability and no restriction on debt size. - Capital allocation plans include organic capex post stabilization of the injectables business and potential inorganic opportunities (M&A) if synergistic fits arise. - No explicit mention of immediate or planned equity fundraising. - The focus is on using existing cash and debt capacity for expansion, including Plant 6 capex planned for FY '26. - Dividend policy remains firm at 20% of profits, indicating available cash flow for shareholder returns alongside growth investments. In summary, Windlas Biotech is well-capitalized with available cash and borrowing capacity but has not indicated any immediate new fundraising through debt or equity.

Order book

→The call transcript does not specify the current or expected order book or pending orders quantitatively.
→It mentions that the injectable facility has been approved by several large customers and some injectable products have been commercialized.
→Management highlights active efforts on trade generics and CDMO verticals with new customer additions and broader product portfolios.
→There are ongoing initiatives in export verticals, including filing dossiers and entering newer markets, indicating pipeline building.
→Plant 6 oral solids facility is being modernized and expected to be operational within FY '26 to support growth.
→Overall, the company is optimistic about order growth driven by trade generics, injectables ramp-up, and exports but does not disclose specific order book figures.

Capex plans

Yes

- Windlas Biotech plans organic capex primarily after stabilizing the injectables business. - Capex for Plant 6 is planned to be executed during FY '26. - Expansion in dosage forms is targeted, with ongoing exploration of inorganic opportunities like M&A if synergistic fits arise. - Sufficient cash (INR 215+ crores) and debt-taking capacity provide flexibility for acquisition or organic growth. - The company prioritizes stabilizing the injectable business before further organic expansion. - Dividend policy is maintained at 20% of profits barring exceptions. - Future capital allocation depends on opportunities that do not require extensive turnaround efforts. This outlines planned and contingent capital investments focused on capacity expansion and strategic growth post-injectable business stabilization.

How does Windlas Biotech Ltd rank vs peers in ?

Pro feature

1Windlas Biotech Ltd

Rev 2Mar 3

See full sector rankings

Want more stocks like Windlas Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio